Uterine Fibroids Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Abbvie, Tium Bio, Ogeda, Bayer, ObsEva

The Uterine Fibroids Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Uterine Fibroids Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Uterine Fibroids Market.

Some of the key takeaways from the Uterine Fibroids Pipeline Report:

• Companies across the globe are diligently working toward developing novel Uterine Fibroids treatment therapies with a considerable amount of success over the years. 
• Uterine Fibroids companies working in the treatment market are Tium Bio, Ogeda, Bayer, ObsEva SA, Repros Therapeutics Inc., InSightec, Myovant Sciences GmbH, AbbVie, Takeda, PregLem SA, and others, are developing therapies for the Uterine Fibroids treatment 

• Emerging Uterine Fibroids therapies in the different phases of clinical trials are- TU2670, Fezolinetant, Vilaprisan, Linzagolix choline, Progenta, ExAblate 2000, Relugolix, Vilaprisan (BAY1002670), Elagolix, Leuprorelin (GF), PGL4001, and others are expected to have a significant impact on the Uterine Fibroids market in the coming years.   
• In December 2020, Additional Phase 3 PRIMROSE 1 and 2 research findings were released by ObsEva SA, demonstrating the continued efficacy and safety of linzagolix in the treatment of uterine fibroids. According to the Week 52 PRIMROSE1 results, linzagolix medication remained to be effective in reducing heavy menstrual bleeding, which was defined as monthly blood loss of at least 50% less than baseline and at or below 80 mL.

Uterine Fibroids Overview

Uterine fibroids are benign (not cancerous) growths that originate in the uterus’s muscle tissue. Myomas or leiomyomas are other names for them. Fibroids can come in a variety of sizes, shapes, and locations. They could be linked to the uterus by a stem-like structure, be located inside the uterus, on its exterior, or even inside its wall.

Get a Free Sample PDF Report to know more about Uterine Fibroids Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/uterine-fibroids-pipeline-insight

Emerging Uterine Fibroids Drugs Under Different Phases of Clinical Development Include:

• TU2670: Tium Bio
• Fezolinetant: Ogeda
• Vilaprisan : Bayer HealthCare Pharmaceuticals
• Linzagolix choline: ObsEva SA
• Progenta: Repros Therapeutics Inc.
• ExAblate 2000: InSightec
• Relugolix: Myovant Sciences GmbH
• Vilaprisan (BAY1002670): Bayer
• Elagolix: AbbVie
• Leuprorelin (GF): Takeda
• PGL4001: PregLem SA

Uterine Fibroids Route of Administration

Uterine Fibroids pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Uterine Fibroids Molecule Type

Uterine Fibroids Products have been categorized under various Molecule types, such as

• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Uterine Fibroids Pipeline Therapeutics Assessment

• Uterine Fibroids Assessment by Product Type
• Uterine Fibroids By Stage and Product Type
• Uterine Fibroids Assessment by Route of Administration
• Uterine Fibroids By Stage and Route of Administration
• Uterine Fibroids Assessment by Molecule Type
• Uterine Fibroids by Stage and Molecule Type

DelveInsight’s Uterine Fibroids Report covers around 25+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Uterine Fibroids product details are provided in the report. Download the Uterine Fibroids pipeline report to learn more about the emerging Uterine Fibroids therapies

Some of the key companies in the Uterine Fibroids Therapeutics Market include:

Key companies developing therapies for Uterine Fibroids are – Myovant Sciences GmbH, Gynesonics, Medtronic, Boston Scientific Corporation, INSIGHTEC, Hologic, Inc., Karl Storz Gmbh, Minerva Surgical, Inc, Pfizer, Inc, Abbvie, Inc, ObsEva, and others.

Uterine Fibroids Pipeline Analysis:

The Uterine Fibroids pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Uterine Fibroids with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Uterine Fibroids Treatment.
• Uterine Fibroids key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Uterine Fibroids Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Uterine Fibroids market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Uterine Fibroids drugs and therapies

Uterine Fibroids Pipeline Market Drivers

• Increase in the number of patients suffering from Uterine fibroids, increasing awareness about the disease are some of the important factors that are fueling the Uterine Fibroids Market.

Uterine Fibroids Pipeline Market Barriers

• However, higher cost of research and development and other factors are creating obstacles in the Uterine Fibroids Market growth.

Scope of Uterine Fibroids Pipeline Drug Insight    

• Coverage: Global
• Key Uterine Fibroids Companies: Tium Bio, Ogeda, Bayer, ObsEva SA, Repros Therapeutics Inc., InSightec, Myovant Sciences GmbH, AbbVie, Takeda, PregLem SA, and others
• Key Uterine Fibroids Therapies: TU2670, Fezolinetant, Vilaprisan, Linzagolix choline, Progenta, ExAblate 2000, Relugolix, Vilaprisan (BAY1002670), Elagolix, Leuprorelin (GF), PGL4001, and others
• Uterine Fibroids Therapeutic Assessment: Uterine Fibroids current marketed and Uterine Fibroids emerging therapies
• Uterine Fibroids Market Dynamics: Uterine Fibroids market drivers and Uterine Fibroids market barriers 

Request for Sample PDF Report for Uterine Fibroids Pipeline Assessment and clinical trials

Table of Contents 

1. Uterine Fibroids Report Introduction

2. Uterine Fibroids Executive Summary

3. Uterine Fibroids Overview

4. Uterine Fibroids- Analytical Perspective In-depth Commercial Assessment

5. Uterine Fibroids Pipeline Therapeutics

6. Uterine Fibroids Late Stage Products (Phase II/III)

7. Uterine Fibroids Mid Stage Products (Phase II)

8. Uterine Fibroids Early Stage Products (Phase I)

9. Uterine Fibroids Preclinical Stage Products

10. Uterine Fibroids Therapeutics Assessment

11. Uterine Fibroids Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Uterine Fibroids Key Companies

14. Uterine Fibroids Key Products

15. Uterine Fibroids Unmet Needs

16 . Uterine Fibroids Market Drivers and Barriers

17. Uterine Fibroids Future Perspectives and Conclusion

18. Uterine Fibroids Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services